Amphastar Pharmaceuticals (AMPH) Common Equity (2013 - 2026)

Amphastar Pharmaceuticals has reported Common Equity for 14 years, with the latest figure at $768.2 million in Q2 2026.

• On a quarterly basis, Common Equity rose 1.41% year-over-year to $768.2 million in Q2 2026; TTM through Jun 2026 was $768.2 million, a 1.41% increase from a year earlier, with the FY2025 full-year figure at $788.8 million, up 7.72% from the prior year.
• Common Equity was $768.2 million for Q2 2026 at Amphastar Pharmaceuticals, down from $773.4 million in the prior quarter.
• The five-year high for Common Equity was $788.8 million in Q4 2025, with the low at $479.5 million in Q1 2022.
• Average Common Equity over 5 years is $658.1 million, with a median of $692.9 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: Common Equity climbed 22.56% in 2024, then grew 1.41% in 2026.
• Over 5 years, Common Equity stood at $528.7 million in 2022, then gained by 20.95% to $639.4 million in 2023, then advanced by 14.53% to $732.3 million in 2024, then gained by 7.72% to $788.8 million in 2025, then slipped by 2.62% to $768.2 million in 2026.
• The last three Common Equity figures came in at $768.2 million (Q2 2026), $773.4 million (Q1 2026), and $788.8 million (Q4 2025), per Business Quant data.